Higher p-4EBP1 level indicated an unfavorable 3-year overall survival among patients with cholangiocarcinoma (P = 0.007), esophageal cancer (P = 0.03), lung cancer (P = 0.03), nasopharyngeal cancer (P = 0.02), ovarian cancer (P = 0.0009), pancreatic cancer (P = 0.02), and other types (P = 0.02). This evidence concerns the gene EIF4EBP1 and lung cancer.